Drug profile · INN
erythromycin lactobionate
ERYTHROMYCIN
erythromycin lactobionate (ERYTHROMYCIN) is a bacterial 70s ribosome inhibitor. Associated with Teva Pharma GmbH. Route of administration: injection. Current US regulatory status: approved.
Drug details — erythromycin lactobionate
- US status
- approved
- Class
- —
- Route
- INJECTION
- Patents
- 2
- Programs
- 10
- Data quality
- 0.89
Quick answer
erythromycin lactobionate (ERYTHROMYCIN) is a bacterial 70s ribosome inhibitor. Associated with Teva Pharma GmbH. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Bacterial 70S ribosome inhibitor
Primary target: Bacterial 70S ribosome
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Recent coverage
Pipeline programs
Related & competitor drugs
Related patents
Frequently asked questions
What is erythromycin lactobionate?
erythromycin lactobionate (ERYTHROMYCIN) is a bacterial 70s ribosome inhibitor. Associated with Teva Pharma GmbH. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for erythromycin lactobionate?
ERYTHROMYCIN is a marketed brand name for erythromycin lactobionate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of erythromycin lactobionate?
erythromycin lactobionate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.